Alexion Of U.S. Applies For Japan Approval Of Soliris
This article was originally published in PharmAsia News
U.S.-based Alexion Pharmaceuticals has applied in Japan for approval of its Soliris (eculizumab) for treating paroxysmal nocturnal hemoglobinuria blood disorders. Alexion wants to provide the treatment to Japanese who have the rare blood disorder that destroys red cells. The company already has clearance for its PNH treatment in several other countries, including the United States. (Click here for more
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.